{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T13:31:27Z","timestamp":1784035887370,"version":"3.55.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T00:00:00Z","timestamp":1680480000000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s40261-023-01258-7","type":"journal-article","created":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T17:02:31Z","timestamp":1680541351000},"page":"299-306","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Real-Life Experience of Tralokinumab for the Treatment of Adult Patients with Severe Atopic Dermatitis: A Multicentric Prospective Study"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0713-8283","authenticated-orcid":false,"given":"Axel","family":"De Greef","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Dominique","family":"Ghislain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Bulinckx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Coster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"de Halleux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Damsin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Claude","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erwin","family":"Suys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samer","family":"Zoghaib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Baeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,3]]},"reference":[{"issue":"4","key":"1258_CR1","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.jaci.2014.08.008","volume":"134","author":"DY Leung","year":"2014","unstructured":"Leung DY, Guttman-Yassky E. Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches. J Allergy Clin Immunol. 2014;134(4):769\u201379. https:\/\/doi.org\/10.1016\/j.jaci.2014.08.008.","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"1258_CR2","doi-asserted-by":"publisher","first-page":"adv00160","DOI":"10.2340\/00015555-3510","volume":"100","author":"S Bylund","year":"2020","unstructured":"Bylund S, Kobyletzki LB, Svalstedt M, Svensson \u00c5. Prevalence and incidence of atopic dermatitis: a systematic review. Acta Derm Venereol. 2020;100(12):adv00160. https:\/\/doi.org\/10.2340\/00015555-3510.","journal-title":"Acta Derm Venereol."},{"issue":"2","key":"1258_CR3","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.anai.2019.04.020","volume":"123","author":"JI Silverberg","year":"2019","unstructured":"Silverberg JI. Comorbidities and the impact of atopic dermatitis. Ann Allergy Asthma Immunol. 2019;123(2):144\u201351. https:\/\/doi.org\/10.1016\/j.anai.2019.04.020.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"1258_CR4","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1111\/all.1340","volume":"73","author":"S Barbarot","year":"2018","unstructured":"Barbarot S, Auziere S, Gadkari A, et al. Epidemiology of atopic dermatitis in adults: results from an international survey. Allergy. 2018;73(6):1284\u201393. https:\/\/doi.org\/10.1111\/all.1340.","journal-title":"Allergy"},{"issue":"4","key":"1258_CR5","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.anai.2020.12.020","volume":"126","author":"JI Silverberg","year":"2021","unstructured":"Silverberg JI, Barbarot S, Gadkari A, et al. Atopic dermatitis in the pediatric population: a cross-sectional, international epidemiologic study. Ann Allergy Asthma Immunol. 2021;126(4):417-428.e2. https:\/\/doi.org\/10.1016\/j.anai.2020.12.020.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"11","key":"1258_CR6","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1007\/s40265-020-01335-7","volume":"80","author":"M Newsom","year":"2020","unstructured":"Newsom M, Bashyam AM, Balogh EA, Feldman SR, Strowd LC. New and emerging systemic treatments for atopic dermatitis. Drugs. 2020;80(11):1041\u201352. https:\/\/doi.org\/10.1007\/s40265-020-01335-7.","journal-title":"Drugs"},{"issue":"4","key":"1258_CR7","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1080\/14656566.2021.1999412","volume":"23","author":"VN Sahni","year":"2022","unstructured":"Sahni VN, Balogh EA, Strowd LC, Feldman SR. The evolving atopic dermatitis management landscape. Expert Opin Pharmacother. 2022;23(4):517\u201326. https:\/\/doi.org\/10.1080\/14656566.2021.1999412.","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"1258_CR8","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/all.13954","volume":"75","author":"T Bieber","year":"2020","unstructured":"Bieber T. Interleukin-13: targeting an underestimated cytokine in atopic dermatitis. Allergy. 2020;75(1):54\u201362. https:\/\/doi.org\/10.1111\/all.13954.","journal-title":"Allergy"},{"issue":"3","key":"1258_CR9","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/bjd.19574","volume":"184","author":"A Wollenberg","year":"2021","unstructured":"Wollenberg A, Blauvelt A, Guttman-Yassky E, et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021;184(3):437\u201349. https:\/\/doi.org\/10.1111\/bjd.19574.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1258_CR10","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/bjd.19573","volume":"184","author":"JI Silverberg","year":"2021","unstructured":"Silverberg JI, Toth D, Bieber T, et al. Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial. Br J Dermatol. 2021;184(3):450\u201363. https:\/\/doi.org\/10.1111\/bjd.19573.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1258_CR11","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/bjd.20832","volume":"186","author":"J Gutermuth","year":"2022","unstructured":"Gutermuth J, Pink AE, Worm M, Soldbro L, Bjerreg\u00e5rd\u00d8land C, Weidinger S. Tralokinumab plus topical corticosteroids in adults with severe atopic dermatitis and inadequate response to or intolerance of ciclosporin A: a placebo-controlled, randomized, phase III clinical trial (ECZTRA 7). Br J Dermatol. 2022;186(3):440\u201352. https:\/\/doi.org\/10.1111\/bjd.20832.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1258_CR12","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.jaad.2003.08.003","volume":"52","author":"JM Hanifin","year":"2005","unstructured":"Hanifin JM, Cooper KD, Ho VC, et al. Guidelines of care for atopic dermatitis, developed in accordance with the American Academy of Dermatology (AAD)\/American Academy of Dermatology Association \u201cAdministrative Regulations for Evidence-Based Clinical Practice Guidelines.\u201d J Am Acad Dermatol. 2005;52(1):156. https:\/\/doi.org\/10.1016\/j.jaad.2003.08.003.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1258_CR13","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.jaad.2022.07.019","volume":"87","author":"A Blauvelt","year":"2022","unstructured":"Blauvelt A, Langley RG, Lacour JP, et al. Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: interim analysis of the ECZTEND open-label extension trial. J Am Acad Dermatol. 2022;87(4):815\u201324. https:\/\/doi.org\/10.1016\/j.jaad.2022.07.019.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1258_CR14","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.jaad.2019.02.053","volume":"81","author":"S Faiz","year":"2019","unstructured":"Faiz S, Giovannelli J, Podevin C, et al. Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort. J Am Acad Dermatol. 2019;81(1):143\u201351. https:\/\/doi.org\/10.1016\/j.jaad.2019.02.053.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1258_CR15","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.3390\/jcm9061982","volume":"9","author":"DH Jang","year":"2020","unstructured":"Jang DH, Heo SJ, Jung HJ, Park MY, Seo SJ, Ahn J. Retrospective study of dupilumab treatment for moderate to severe atopic dermatitis in Korea: efficacy and safety of dupilumab in real-world practice. J Clin Med. 2020;9(6):1982. https:\/\/doi.org\/10.3390\/jcm9061982.","journal-title":"J Clin Med"},{"key":"1258_CR16","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/cia2.12099","volume":"3","author":"M Matstutani","year":"2020","unstructured":"Matstutani M, Imai Y, Inoue Y, et al. Real-world use of dupilumab for 53 patients with atopic dermatitis in Japan. J Cutan Immunol Allergy. 2020;3:35\u20136. https:\/\/doi.org\/10.1002\/cia2.12099.","journal-title":"J Cutan Immunol Allergy."},{"issue":"5","key":"1258_CR17","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1001\/jamadermatol.2022.0455","volume":"158","author":"AM Drucker","year":"2022","unstructured":"Drucker AM, Morra DE, Prieto-Merino D, et al. Systemic immunomodulatory treatments for atopic dermatitis: update of a living systematic review and network meta-analysis. JAMA Dermatol. 2022;158(5):523\u201332. https:\/\/doi.org\/10.1001\/jamadermatol.2022.0455.","journal-title":"JAMA Dermatol"},{"issue":"9","key":"1258_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013206.pub2","volume":"9","author":"R Sawangjit","year":"2020","unstructured":"Sawangjit R, Dilokthornsakul P, Lloyd-Lavery A, Lai NM, Dellavalle R, Chaiyakunapruk N. Systemic treatments for eczema: a network meta-analysis. Cochrane Database Syst Rev. 2020;9(9): CD013206. https:\/\/doi.org\/10.1002\/14651858.CD013206.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"1258_CR19","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.21867","author":"EL Simpson","year":"2022","unstructured":"Simpson EL, Merola JF, Silverberg JI, et al. Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials [published online ahead of print, 2022 Sep 9]. Br J Dermatol. 2022. https:\/\/doi.org\/10.1111\/bjd.21867.","journal-title":"Br J Dermatol"},{"issue":"6","key":"1258_CR20","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1111\/jdv.17981","volume":"36","author":"N Neagu","year":"2022","unstructured":"Neagu N, Dianzani C, Avallone G, et al. Dupilumab ocular side effects in patients with atopic dermatitis: a systematic review. J Eur Acad Dermatol Venereol. 2022;36(6):820\u201335. https:\/\/doi.org\/10.1111\/jdv.17981.","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-023-01258-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-023-01258-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-023-01258-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T15:27:04Z","timestamp":1681313224000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-023-01258-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["1258"],"URL":"https:\/\/doi.org\/10.1007\/s40261-023-01258-7","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"8 March 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was used to conduct this study.\u00a0Open Access fee was\u00a0funded by the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Axel De Greef, Pierre-Dominique Ghislain and Marie Baeck disclose their past participation on the tralokinumab advisory board organized by LEO Pharma but declare that the current study was conducted in an independent manner. Pierre-Dominique Ghislain received consultancy fees for expert work in clinical trials with other drugs from LEO Pharma. Audrey Bulinckx, Alison Coster, C\u00e9line de Halleux, Thomas Damsin, Marie-Claude Jacobs, Erwin Suys and Samer Zoghaib disclose no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The datasets generated during and\/or analysed during the current study are available from the corresponding author on reasonable request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"This study and data collection were conducted with the approval of the hospital and faculty institutional review board (Commission d\u2019Ethique Biom\u00e9dicale Hospitalo-Facultaire) of Universit\u00e9 catholique de Louvain (UCLouvain), Belgium. All procedures in this study were in accordance with the 1964 Helsinki declaration (and its amendments).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The patients in this manuscript have given written informed consent to participate and for publication of their case details.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for participation\/publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"ADG: conceptualization, methodology, validation, formal analysis, investigation, resources, data curation, writing\u2014original draft, visualization; PDG: data curation, investigation, writing\u2014review and editing, supervision; AB: investigation, data curation; AC: investigation, data curation; CdH: investigation, data curation; TD: investigation, data curation; MCJ: investigation, data curation; ES: investigation, data curation; SZ: investigation, data curation; MB: conceptualization, methodology, validation, formal analysis, investigation, resources, data curation, writing\u2014review and editing, supervision.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors contribution"}}]}}